Loading
Life sciences · Journal article
Discover Oncology · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chimeric antigen receptor (CAR)-T cell therapy in solid tumours is frequently limited by progressive functional impairment and inadequate metabolic fitness within the tumour microenvironment. Mitochondrial transcription elongation factor (TEFM) is an essential regulator of mitochondrial gene expression, but its role in CAR-T-cell engineering remains unknown. In this study, we developed TEFM mRNA-loaded lipid nanoparticles (TEFM mRNA-LNPs) to transiently increase TEFM expression in CAR-T cells and investigated their effects on mitochondrial function and antitumour activity. TEFM mRNA-LNP transfection significantly increased intracellular TEFM expression and enhanced CAR-T-cell cytotoxicity, activation and cytokine production in vitro. TEFM augmentation also increased mitochondrial membrane potential, oxygen consumption and ATP production while reducing mitochondrial reactive oxygen species. In an OVCAR-3 intraperitoneal metastasis model, TEFM-engineered CAR-T cells achieved improved tumour control and prolonged mouse survival without overt histopathological abnormalities in major organs. Tumour tissues from mice treated with TEFM CAR-T cells also exhibited increased intratumoural cytokine levels and enhanced local effector activity. Collectively, these findings demonstrate that transient TEFM augmentation improves mitochondrial fitness and potentiates the effector and antitumour activities of CAR-T cells, supporting a mitochondria-directed strategy for the metabolic engineering of adoptive cell therapies.